دورية أكاديمية
Predictors of Cognitive Change in Parkinson Disease: A 2-year Follow-up Study.
| العنوان: | Predictors of Cognitive Change in Parkinson Disease: A 2-year Follow-up Study. |
|---|---|
| المؤلفون: | Gasca-Salas C; HM CINAC (Centro Integral de Neurociencias Abarca Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales.; Network Center for Biomedical Research on Neurodegenerative Diseases (CIBERNED), Instituto Carlos III.; University CEU-San Pablo, Madrid, Spain., Duff-Canning S; The Edmond J Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University of Toronto., McArthur E; London Health Sciences Centre, London, ON, Canada., Armstrong MJ; Department of Neurology, University of Florida College of Medicine; Gainesville, FL., Fox S; The Edmond J Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University of Toronto., Meaney CA; Department of Family and Community Medicine, University of Toronto., Tang-Wai DF; Department of Medicine (Neurology), University of Toronto, University Health Network Memory Clinic., Gill D; Department of Neurology, Rochester Regional Health., Eslinger PJ; Department of Neurology, Penn State Hershey Medical Center, Hershey, PA., Zadikoff C; Department of Neurology, Northwestern University.; AbbVie Inc., North Chicago., Marshall FJ; Department of Neurology, University of Rochester, Rochester, NY., Mapstone M; Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL., Chou KL; Departments of Neurology and Neurosurgery., Persad C; Psychiatry, Michigan Medicine, University of Michigan, Ann Arbor, MI., Litvan I; Department of Neurosciences, Parkinson and Other Movement Disorders Center UC San Diego, La Jolla, CA., Mast BT; Psychological & Brain Sciences, University of Louisville, Louisville, KY., Gerstenecker AT; Department of Neurology, Division of Neuropsychology, University of Alabama at Birmingham, Birmingham, AL., Weintraub S; Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL., Marras C; The Edmond J Safra Program in Parkinson's disease, University Health Network, University of Toronto, Toronto. |
| المصدر: | Alzheimer disease and associated disorders [Alzheimer Dis Assoc Disord] 2023 Oct-Dec 01; Vol. 37 (4), pp. 335-342. Date of Electronic Publication: 2023 Aug 22. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8704771 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-4156 (Electronic) Linking ISSN: 08930341 NLM ISO Abbreviation: Alzheimer Dis Assoc Disord Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Hagerstown, MD : Lippincott Williams & Wilkins Original Publication: Lawrence, Kan. : Western Geriatric Research Institute, c1987- |
| مواضيع طبية MeSH: | Parkinson Disease*/complications , Parkinson Disease*/diagnosis , Cognitive Dysfunction*/diagnosis , Cognitive Dysfunction*/complications , Dementia*/diagnosis, Humans ; Follow-Up Studies ; Cognition ; Neuropsychological Tests |
| مستخلص: | Background: Mild cognitive impairment is common in Parkinson disease (PD-MCI). However, instability in this clinical diagnosis and variability in rates of progression to dementia raises questions regarding its utility for longitudinal tracking and prediction of cognitive change in PD. We examined baseline neuropsychological test and cognitive diagnosis predictors of cognitive change in PD. Methods: Persons with PD, without dementia PD (N=138) underwent comprehensive neuropsychological assessment at baseline and were followed up to 2 years. Level II Movement Disorder Society criteria for PD-MCI and PD dementia (PDD) were applied annually. Composite global and domain cognitive z -scores were calculated based on a 10-test neuropsychological battery. Results: Baseline diagnosis of PD-MCI was not associated with a change in global cognitive z -scores. Lower baseline attention and higher executive domain z -scores were associated with greater global cognitive z -score worsening regardless of cognitive diagnosis. Worse baseline domain z -scores in the attention and language domains were associated with progression to MCI or PDD, whereas higher baseline scores in all cognitive domains except executive function were associated with clinical and psychometric reversion to "normal" cognition. Conclusions: Lower scores on cognitive tests of attention were predictive of worse global cognition over 2 years of follow-up in PD, and lower baseline attention and language scores were associated with progression to MCI or PDD. However, PD-MCI diagnosis per se was not predictive of cognitive decline over 2 years. The association between higher executive domain z -scores and greater global cognitive worsening is probably a spurious result. Competing Interests: The authors declare no conflicts of interest. (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.) |
| References: | Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–194. Litvan I, Goldman JG, Tröster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012;27:349–356. Pedersen KF, Larsen JP, Tysnes OB, et al. Natural course of mild cognitive impairment in Parkinson disease: a 5-year population-based study. Neurology. 2017;88:767–774. Lawson RA, Yarnall AJ, Duncan GW, et al. ICICLE-PD study group. Stability of mild cognitive impairment in newly diagnosed Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2017;88:648–652. Galtier I, Nieto A, Lorenzo JN, et al. Mild cognitive impairment in Parkinson’s disease: diagnosis and progression to dementia. J Clin Exp Neuropsychol. 2016;38:40–50. Saredakis D, Collins-Praino LE, Gutteridge DS, et al. Conversion to MCI and dementia in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2019;65:20–31. Hoogland J, Boel JA, de Bie RMA, et al. Mild cognitive impairment as a risk factor for Parkinson’s disease dementia. Mov Disord. 2017;32:1056–1065. Hoogland J, Boel JA, de Bie RMA, et al. Risk of Parkinson’s disease dementia related to level I MDS PD-MCI. Mov Disord. 2019;34:430–435. Marras C, Armstrong MJ, Meaney CA, et al. Measuring mild cognitive impairment in patients with Parkinson’s disease. Mov Disord. 2013;28:626–633. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009;132:2958–2969. Hobson P, Meara J. Mild cognitive impairment in Parkinson’s disease and its progression onto dementia: a 16-year outcome evaluation of the Denbighshire cohort. Int J Geriatr Psychiatry. 2015;30:1048–1055. Pagonabarraga J, Kulisevsky J. Cognitive impairment and dementia in Parkinson’s disease. Neurobiol Dis. 2012;46:590–596. Delis DC, Kaplan E, Kramer JH. Delis–Kaplan Executive Function System (D-KEFS): Examiner’s Manual. The Psychological Corporation; 2001. Wechsler D. Wechsler Memory Scale. The Psychological Corporation; 1997. Williams BW, Mack W, Henderson VW. Boston naming test in Alzheimer’s disease. Neuropsychologia. 1989;27:1073–1079. Benton AL, Sivan AB, Hamsher K, et al. Contributions to Neuropsychological Assessment: A Clinical Manual. Oxford; 1994. Meyers JE, Meyers KR. Rey Complex Figure Test and Recognition Trial—Professional Manual. Psychological Assessment Resources; 1995. Delis D, Kramer JH, Kaplan E. The California Verbal Learning Test. The Psychological Corporation; 2000. Strauss E, Sherman EMS, Spreen O. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. Oxford University Press; 2006. Wicklund AH, Johnson N, Weintraub S. Preservation of reasoning in primary progressive aphasia: further differentiation from Alzheimer’s disease and the behavioral presentation of frontotemporal dementia. J Clin Exp Neuropsychol. 2004;26:347–355. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22:1689–1707. Wood KL, Myall DJ, Livingston L, et al. Different PD-MCI criteria and risk of dementia in Parkinson’s disease: 4-year longitudinal study. NPJ Parkinsons Dis. 2016;2:15027. Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004;19:203–214. Lansing AE, Ivnik RJ, Callum CM, et al. An empirically derived short form of the boston naming test. Arch Clin Neuropsychol. 1999;14:481–487. SAS Institute Inc. SAS® 94 Procedures Guide: Reference. SAS Institute Inc; 2013. Armstrong MJ, Naglie G, Duff-Canning S, et al. Roles of education and IQ in cognitive reserve in Parkinson’s disease-mild cognitive impairment. Dement Geriatr Cogn Dis Extra. 2012;2:343–352. Di Battista ME, Rubino A, Valente M, et al. Is cognitive stability in Parkinson’s disease a predictable phenomenon? A 5-year follow-up study. J Neural Transm (Vienna). 2015;122:1703–1706. Pedersen KF, Larsen JP, Tysnes OB, et al. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol. 2013;70:580–586. Broeders M, de Bie RM, Velseboer DC, et al. Evolution of mild cognitive impairment in Parkinson disease. Neurology. 2013;81:346–352. Jones JD, Kuhn TP, Szymkowicz SM. Reverters from PD-MCI to cognitively intact are at risk for future cognitive impairment: analysis of the PPMI cohort. Parkinsonism Relat Disord. 2018;47:3–7. Chung SJ, Park YH, Yoo HS, et al. Mild cognitive impairment reverters have a favorable cognitive prognosis and cortical integrity in Parkinson’s disease. Neurobiol Aging. 2019;78:168–177. Santangelo G, Vitale C, Picillo M, et al. Mild Cognitive Impairment in newly diagnosed Parkinson’s disease: a longitudinal prospective study. Parkinsonism Relat Disord. 2015;21:1219–1226. Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson’s disease. Neurosci Biobehav Rev. 2006;30:1–23. Pascual-Sedano B, Kulisevsky J, Barbanoj M, et al. Levodopa and executive performance in Parkinson’s disease: a randomized study. J Int Neuropsychol Soc. 2008;14:832–841. AlDakheel A, Gasca-Salas C, Armstrong MJ, et al. Cognitive complaints in nondemented Parkinson's disease patients and their close contacts do not predict worse cognitive outcome. Alzheimer Dis Assoc Disord. 2019;33:147–153. Gasca-Salas C, Duff-Canning S, Armstrong MJ, et al. Parkinson disease with mild cognitive impairment: domain-specific cognitive complaints predict dementia. Acta Neurol Scand. 2020;142:585–596. Gasca-Salas C, Estanga A, Clavero P, et al. Longitudinal assessment of the pattern of cognitive decline in non-demented patients with advanced Parkinson’s disease. J Parkinsons Dis. 2014;4:677–686. Muslimovic D, Post B, Speelman JD, et al. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 2005;65:1239–1245. Kehagia AA, Barker RA, Robbins TW. Cognitive impairment in Parkinson’s disease: the dual syndrome hypothesis. Neurodegener Dis. 2013;11:79–92. Lewis SJ, Slabosz A, Robbins TW, et al. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson’s disease. Neuropsychologia. 2005;43:823–832. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol. 2006;253:242–247. Zgaljardic DJ, Foldi NS, Borod JC. Cognitive and behavioral dysfunction in Parkinson’s disease: neurochemical and clinicopathological contributions. J Neural Transm (Vienna). 2004;111:1287–1301. Taylor JP, Rowan EN, Lett D, et al. Poor attentional function predicts cognitive decline in patients with non-demented Parkinson’s disease independent of motor phenotype. J Neurol Neurosurg Psychiatry. 2008;79:1318–1323. Gasca-Salas C, Duff-Canning S, Armstrong MJ, et al. Parkinson disease with mild cognitive impairment: domain-specific cognitive complaints predict dementia. Acta Neurol Scand. 2020;142:585–596. Pigott K, Rick J, Xie SX, et al. Longitudinal study of normal cognition in Parkinson disease. Neurology. 2015;85:1276–1282. Tröster AI, Woods SP, Morgan EE. Assessing cognitive change in Parkinson’s disease: development of practice effect-corrected reliable change indices. Arch Clin Neuropsychol. 2007;22:711–718. Aarsland D, Batzu L, Halliday GM, et al. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers. 2021;7:47. |
| معلومات مُعتمدة: | K08 HS024159 United States HS AHRQ HHS; P50 AG047266 United States AG NIA NIH HHS; R01 AG047992 United States AG NIA NIH HHS; R01 ES019672 United States ES NIEHS NIH HHS; R01 AG070088 United States AG NIA NIH HHS; P50 NS091856 United States NS NINDS NIH HHS; U01 NS100611 United States NS NINDS NIH HHS; R01 AG038791 United States AG NIA NIH HHS; U01 NS100610 United States NS NINDS NIH HHS; U01 NS080818 United States NS NINDS NIH HHS; R25 NS098999 United States NS NINDS NIH HHS; U19 AG063911 United States AG NIA NIH HHS; R21 NS114764 United States NS NINDS NIH HHS; P30 AG013854 United States AG NIA NIH HHS; U2C AG057441 United States AG NIA NIH HHS; U01 NS105562 United States NS NINDS NIH HHS; DP2 AG058487 United States AG NIA NIH HHS; U54 NS092089 United States NS NINDS NIH HHS; U01 AG010483 United States AG NIA NIH HHS; U01 AG016976 United States AG NIA NIH HHS; R01 AG056258 United States AG NIA NIH HHS; R01 DC008552 United States DC NIDCD NIH HHS; R01 AG045571 United States AG NIA NIH HHS; U01 AG052943 United States AG NIA NIH HHS |
| تواريخ الأحداث: | Date Created: 20230824 Date Completed: 20231129 Latest Revision: 20231212 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1097/WAD.0000000000000576 |
| PMID: | 37615480 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!